eMed Appoints Linda Yaccarino as New CEO to Drive Digital Health Revolution

Strategic Insights -

The eMed Population Health digital health platform has announced the appointment of Linda Yaccarino, former CEO of X, as its new CEO. Yaccarino's hiring marks a significant moment for eMed's mission to make chronic care accessible through a digital-first experience. Her experience in leading paradigm-shifting transformations is expected to bring a new dimension to the company.

Key Takeaways:

  • Linda Yaccarino, former CEO of X, has been appointed as the new CEO of eMed Population Health digital health platform.
  • Yaccarino's hiring is expected to drive eMed's mission to make safe, effective, and sustainable chronic care accessible directly through an all-in-one, digital-first experience.
  • eMed is currently working on a population health management platform for GLP-1 weight loss and diabetes drugs.
  • Goldman Sachs researchers estimate that about 15 million adults in the United States may be treated with anti-obesity medications (AOMs) by 2030, with the industry reaching $100 billion in annual revenue by that year.
  • Yaccarino believes there is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly.
  • eMed's appointment of Yaccarino marks a significant moment in the company's mission to transform the healthcare industry through technology.
  • Yaccarino's experience and expertise are expected to drive eMed's growth and success in the digital health space.
  • eMed's population health management platform aims to revolutionize the way chronic care is delivered and accessed.

Statistics:

  • 15 million adults in the United States are expected to be treated with anti-obesity medications (AOMs) by 2030 (Source: Goldman Sachs).
  • The anti-obesity medication industry could reach $100 billion in annual revenue by 2030 (Source: Goldman Sachs).
  • eMed is currently working on a population health management platform for GLP-1 weight loss and diabetes drugs.
  • Yaccarino has a 2-year tenure as CEO of X, prior to her resignation in July 2023.

Sources:

  • UPI, Aug. 5, 2023
  • eMed press release, Aug. 5, 2023
  • Goldman Sachs research report (no specific date mentioned)
  • X press release (no specific date mentioned)